MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in laboratories; and specialty chemicals and functional materials for use in consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc., Baylor College of Medicine, Bristol-Myers Squibb Company, Intrexon Corporation, F-star Delta Ltd, Alibaba Health, and Checkmate Pharmaceuticals. The company also has collaboration with the Solvias to offer the PyroMAT system, a MAT kit for pyrogen detection; Immutep Limited; Leap Therapeutics, Inc.; and Personal Genome Diagnostics Inc. In addition, MERCK Kommanditgesellschaft auf Aktien has a collaboration with Daiichi Sankyo Company, Limited to evaluate the combination of DS-8201, an investigational HER2 targeting antibody drug conjugate; and a strategic alliance with genOway S.A. to develop CRISPR/Cas9-related products and solutions, as well as with GSK to develop and commercialize M7824, which is in Phase II trial for treating patients with PD-L1 expressing non-small cell lung cancer. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
